Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Opioid-Related Disorders × Tirzepatide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 8 Endometrial Neoplasms 4 Prostatic Neoplasms 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Overweight 1 Opioid-Related Disorders 1 Metabolic Syndrome 1 Lymphoma, Follicular 1 Insulin Resistance 1 Inflammation 1 Hyperplasia 1 Dyslipidemias 1 Colorectal Neoplasms 1

Interventions

Standard of Care 2 methylnaltrexone 1 acetaminophen, codeine drug combination 1 Ultrasonic Waves 1 Tramadol 1 Tirzepatide 1 Therapeutics 1 Sublocade 1 Psilocybin 1 Olanzapine 1 Midazolam 1 Medical Marijuana 1 Lidocaine 1 Educational Status 1 Dosage Forms 1 Capsules 1 Buprenorphine, Naloxone Drug Combination 1 Buprenorphine 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06651177 2026-03-05

TAB

University of Cincinnati

Phase 2 Recruiting

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡